XTL Biopharmaceuticals Ltd.

Regulatory Filings • Nov 18, 2008

_________ false

C002��� �� �� ������������� ��"�2PublicX T L BIOPHARMACEUTICALS LTD4313Corporation no: 520039470Stock Exchange/Market: ��� �� ��1996380Hasapir 3 , Nes Ziona 76100 , ,Tel: 08-9304444 , Fax: 08-9304445E.mail address: rcohen@xtlbio.comDate of transmission: 18/11/2008              Time of broadcast: 15:05 15:05:00

Reference: 2008-02-321801

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on XTL Biopharmaceuticals Announces Top-line results from the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain Study failed to meet its primary endpoint
PressReleaseNegativeFinal_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 16/11/2008
- - -
Name of the Signatory: : Kantor Ronen , Position of Signatory in the reporting corporation: Legal Consultant & Corporate Secretary , Name of Employer Company: .
Abba Hillel Silver Telephone: 03-6133371 , Facsimile: 03-6133372 , E-mail: rkantor@kantor-law.com 2